News articles about ChemoCentryx (NASDAQ:CCXI) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ChemoCentryx earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.0005742791234 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities analysts have commented on CCXI shares. ValuEngine lowered shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. BidaskClub lowered shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. Finally, Cowen reiterated a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.25.
Shares of ChemoCentryx (CCXI) opened at $6.85 on Monday. ChemoCentryx has a fifty-two week low of $6.13 and a fifty-two week high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. equities research analysts anticipate that ChemoCentryx will post -0.67 EPS for the current year.
WARNING: This piece was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://ledgergazette.com/2017/12/04/chemocentryx-ccxi-earning-somewhat-positive-news-coverage-study-finds.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc and related companies with MarketBeat.com's FREE daily email newsletter.